PT  - JOURNAL ARTICLE
AU  - Meng, Zhou
AU  - Le Marchand, Sylvain
AU  - Agnani, Deep
AU  - Szapacs, Matthew
AU  - Ellens, Harma
AU  - Bentz, Joe
TI  - Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers
AID  - 10.1124/dmd.116.072157
DP  - 2017 Feb 01
TA  - Drug Metabolism and Disposition
PG  - 145--151
VI  - 45
IP  - 2
4099  - http://dmd.aspetjournals.org/content/45/2/145.short
4100  - http://dmd.aspetjournals.org/content/45/2/145.full
SO  - Drug Metab Dispos2017 Feb 01; 45
AB  - From fits of drug transport kinetics across confluent MDCKII-hMDR1-NKI and Caco-2 cell monolayers we estimated the levels of efflux active P-glycoprotein (P-gp) in these two cell lines (companion paper). In the present work, we compared the efflux active P-gp number to the total P-gp level, using liquid chromatography–tandem mass spectrometry, and showed that in Caco-2 cells total P-gp is about 10-fold greater than efflux active P-gp, whereas in MDCKII-hMDR1-NKI cells these values are within twofold. We further visualized the microvilli in MDCKII-hMDR1-NKI and Caco-2 cells using three-dimensional structured illumination super-resolution microscopy and found that the microvilli in Caco-2 cells are taller and more densely packed than those in MDCK-hMDR1-NKI cells. We hypothesized over 10 years ago that only P-gp at the tips of the microvilli contribute significantly to efflux activity, whereas the remaining P-gp are involved in a futile cycle of efflux of amphipathic drugs from the microvillus membrane, followed by their reabsorption into the same or nearby microvillous membranes. The difference between the levels of total and efflux active P-gp in Caco-2 cells can be explained by the more densely packed microvilli in Caco-2 cells, which would lead to a substantial fraction of P-gp not contributing to final release of drug into the apical chamber. Our results suggest that the effect of microvilli morphology differences between in vitro and in vivo systems must be considered when scaling transporter activity for efflux transporters of amphipathic compounds, for example, P-gp.